Skip to main content
OpenTrials
Completed

NCT Number: NCT01450540

Automated Graduated CPAP (AGPAP) for Improved Adherence in Newly Diagnosed Obstructive Sleep Apnea (OSA) Patients

Although positive airway pressure (PAP) is a highly effective treatment for sleep apnea, adherence to therapy remains an obstacle. Automated Graduated CPAP (AGPAP), also know as EZ-start, is an extended duration ramp, where the patient receives pressure below their prescription during an acclimation phase. The algorithm gradually increases pressure to therapy level based on usage. The aim of this study was to determine the effectiveness of the AGPAP acclimation period and its impact on short term adherence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Delta Waves Sleep Disorder and Research Center, Colorado Springs, Colorado, United States

Loading trial locations.

About this study

Even though CPAP is highly effective in treating sleep apnea, adherence to CPAP therapy remains the largest single obstacle to the successful resolution of sleep-disordered breathing in OSA patients. It has been estimated that up to 50% of patients who have been prescribed CPAP for Obstructive Sleep Apnea (OSA) are not using the treatment one year later. A myriad of possible causes for low compliance rates have been proposed and examined in previous studies. These include race, gender, education level, income, bed-partner's sleep quality, mask discomfort, continuity of care, nasal irritation, discomfort due to elevated expiratory pressure, and level of daytime sleepiness.

Therefore, many investigators have proposed new methods and approaches to help deal with these problems. Interventions have ranged from people-centric approaches using intensive CPAP education and follow-up programs, to device modifications using features such as a ramp, C-FLEX®, BiLevel therapy, and heated humidification.

In this study. The aim of this study was to determine the effectiveness of the Automated Graduated CPAP (AGPAP), also know as EZ-start acclimation period, and its impact on short term adherence

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed with OSA (last 12 weeks)
  • Prescribed continuous positive airway pressure (CPAP) pressure ≥ 10 cmH2O
  • Willing and able to provide informed consent
  • Able to follow instructions

Exclusion criteria

  • Participation in another interventional research study within the last 30 days
  • Major controlled or an uncontrolled medical condition such as congestive heart failure, neuromuscular disease, renal failure, cancer, chronic obstructive pulmonary disease (COPD), respiratory failure or insufficiency, or patients requiring oxygen therapy (as determined by self-report and reviewed by the study PI.)
  • Prior PAP prescription, use, or any prior OSA treatment, excluding split-night or titration PAP exposure.
  • Prescribed BiLevel therapy
  • Presence of untreated, non-OSA related sleep disorders (e.g. moderate to severe restless legs (PLMAI ≥ 20) or insomnia)
  • History of an automobile accident or near accident in the last 12 months due to sleepiness.
  • Severe oxygen desaturation on the PSG (Sa02 < 70% for 10% of the diagnostic PSG study).
  • Surgery of the upper airway, nose, sinus, or middle ear within the past 90 days
  • Regular use (>3 nights per week) of sleeping pills or stimulants.
  • Currently working a night shift or rotating day/night shift.
  • Unwillingness to try PAP at home.
  • Presence of tracheostomy

Treatment and study plan

REMstar Auto A-Flex

Device

Standard CPAP

Other names: Philips Respironics System One

modified REMstar Auto A-Flex with AGPAP

Device

Modified device -Software upgrade to GP 12

Other names: Philips Respironics System One

Primary outcomes

  1. CPAP Adherence

    Time frame: 3 months

    Device usage (hours per night)

Secondary outcomes

  1. Functional Outcome Sleep Quality (FOSQ)

    Time frame: 3 months

    Functional Outcomes Sleep Questionnaire (FOSQ) is a self-administered instrument designed to assess the impact of excessive sleepiness on daytime function and to quantify improvement after treatment. It contains 30 items divided into 5 subscales: Activity level, vigilance, intimacy and sexual relationships, general productivity, and social outcome. The patient rates the difficulty of performing a given activity on a 4-point scale (no difficulty to extreme difficulty) A mean score is calculated for each scale ranging from 0 (maximum functional impact) to 24 (no functional impact).

  2. Daytime Sleepiness as Measured by the Epworth Sleepiness Scale

    Time frame: 3 months

    Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher is the overall 'daytime sleepiness'.

Sponsors and collaborators

Lead sponsor

Philips Respironics

Industry

Registry information

Official study title

Automated Graduated CPAP (AGPAP) for Improved Adherence in Newly Diagnosed OSA Patients: Multicenter Trial

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Oct 12, 2011
Registry last updated
Mar 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.